Relay Therapeutics Stock Forecast
NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
RLAY analyst consensus
Consensus (13 analysts)
strong_buy
Avg. price target
$27.58+58.41%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Relay Therapeutics (2026-10-07), 13 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $27.58, with a high estimate of $32.00 and a low estimate of $20.00. The average target implies upside of 58.4% from the current price of $17.41.
The spread between the highest and lowest targets is 60.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RLAY.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 23% |
| Buy | 10 | 77% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $20.00 | +14.88% |
| Average target | $27.58 | +58.41% |
| High target | $32.00 | +83.80% |